CL2017002731A1 - Adenovirus oncolítico que codifica una proteína b7 - Google Patents

Adenovirus oncolítico que codifica una proteína b7

Info

Publication number
CL2017002731A1
CL2017002731A1 CL2017002731A CL2017002731A CL2017002731A1 CL 2017002731 A1 CL2017002731 A1 CL 2017002731A1 CL 2017002731 A CL2017002731 A CL 2017002731A CL 2017002731 A CL2017002731 A CL 2017002731A CL 2017002731 A1 CL2017002731 A1 CL 2017002731A1
Authority
CL
Chile
Prior art keywords
protein
oncolytic adenovirus
adenovirus encoding
viruses
compositions
Prior art date
Application number
CL2017002731A
Other languages
English (en)
Inventor
Brian Robert Champion
Alice Claire Noel Bromley
Original Assignee
Psioxus Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1507419.8A external-priority patent/GB201507419D0/en
Priority claimed from GBGB1516936.0A external-priority patent/GB201516936D0/en
Priority claimed from GBGB1522013.0A external-priority patent/GB201522013D0/en
Application filed by Psioxus Therapeutics Ltd filed Critical Psioxus Therapeutics Ltd
Publication of CL2017002731A1 publication Critical patent/CL2017002731A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10371—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

<p>La presente descripción proporciona un adenovirus de replicación oncolítico competente con selectividad para células cancerosas, donde el adenovirus comprende un transgén bajo el control de un promotor endógeno del virus, en el que el transgén comprende una secuencia de ADN que codifica una proteína B7 o un fragmento activo de la misma, composiciones que comprende los mismos, métodos para generar los virus, y uso de los virus y las composiciones en tratamiento, particularmente en el tratamiento del cáncer.</p>
CL2017002731A 2015-04-30 2017-10-26 Adenovirus oncolítico que codifica una proteína b7 CL2017002731A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1507419.8A GB201507419D0 (en) 2015-04-30 2015-04-30 Virus
GBGB1516936.0A GB201516936D0 (en) 2015-09-24 2015-09-24 Virus
GBGB1522013.0A GB201522013D0 (en) 2015-12-14 2015-12-14 Virus

Publications (1)

Publication Number Publication Date
CL2017002731A1 true CL2017002731A1 (es) 2018-06-08

Family

ID=56008588

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2017002731A CL2017002731A1 (es) 2015-04-30 2017-10-26 Adenovirus oncolítico que codifica una proteína b7
CL2018000587A CL2018000587A1 (es) 2015-04-30 2018-03-05 Adenovirus oncolítico que codifica una proteína b7 (divisional de sol. n° 2731-2017)

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2018000587A CL2018000587A1 (es) 2015-04-30 2018-03-05 Adenovirus oncolítico que codifica una proteína b7 (divisional de sol. n° 2731-2017)

Country Status (31)

Country Link
US (6) US11000559B2 (es)
EP (2) EP3391892A1 (es)
JP (3) JP6931229B2 (es)
KR (4) KR102643574B1 (es)
CN (2) CN107690479B (es)
AU (3) AU2016256582B2 (es)
BR (2) BR122018004815A2 (es)
CA (1) CA2984038C (es)
CL (2) CL2017002731A1 (es)
CO (1) CO2017010831A2 (es)
CY (1) CY1122833T1 (es)
DK (1) DK3288573T3 (es)
EA (1) EA037611B1 (es)
ES (1) ES2780366T3 (es)
HR (1) HRP20200439T1 (es)
HU (1) HUE048320T2 (es)
IL (3) IL284375B (es)
LT (1) LT3288573T (es)
MX (1) MX2017013684A (es)
MY (1) MY183703A (es)
PE (2) PE20180241A1 (es)
PH (1) PH12017501942A1 (es)
PL (1) PL3288573T3 (es)
PT (1) PT3288573T (es)
RS (1) RS60105B1 (es)
SA (2) SA517390260B1 (es)
SG (3) SG10201803081TA (es)
SI (1) SI3288573T1 (es)
SM (1) SMT202000222T1 (es)
WO (1) WO2016174200A1 (es)
ZA (1) ZA201801589B (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6797680B2 (ja) 2013-06-14 2020-12-16 サイオクサス セラピューティクス リミテッド Ｂ型アデノウイルスのための投与計画および製剤
GB201322851D0 (en) 2013-12-23 2014-02-12 Psioxus Therapeutics Ltd Method
SI3021859T1 (en) 2013-10-25 2018-04-30 Psioxus Therapeutics Limited Oncolytic adenoviruses equipped with heterologous genes
GB201406608D0 (en) 2014-04-12 2014-05-28 Psioxus Therapeutics Ltd Virus
US11000559B2 (en) 2015-04-30 2021-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding a B7 protein
CA3001131A1 (en) 2015-11-02 2017-05-11 Five Prime Therapeutics, Inc. Cd80 extracellular domain polypeptides and their use in cancer treatment
CN108697745A (zh) * 2015-12-17 2018-10-23 皮斯奥克斯治疗公司 编码抗tcr复合体抗体或片段的b组腺病毒
EP3436591B1 (en) * 2016-03-31 2023-01-04 The European Molecular Biology Laboratory Adenoviral coat protein derived delivery vehicles
IL303187A (en) 2016-08-29 2023-07-01 Akamis Bio Ltd Adenovirus with bispecific T cell activator
GB201713765D0 (en) 2017-08-28 2017-10-11 Psioxus Therapeutics Ltd Modified adenovirus
CN109843922B (zh) 2016-09-02 2023-10-03 莱蒂恩技术公司 用DuoCAR治疗癌症的组合物和方法
EP4019029A1 (en) * 2016-09-27 2022-06-29 Sator Therapeutics LLC Optimized oncolytic viruses and uses thereof
WO2018083257A1 (en) * 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding transgenes
WO2018083258A1 (en) * 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding at least three transgenes
WO2018083259A1 (en) * 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding transgenes
US12350303B2 (en) 2017-02-03 2025-07-08 University of Pittsburgh—of the Commonwealth System of Higher Education Oncolytic virus therapy
CA3057866A1 (en) 2017-04-28 2018-11-01 Five Prime Therapeutics, Inc. Methods of treatment with cd80 extracellular domain polypeptides
IL270876B2 (en) * 2017-05-25 2024-06-01 Univ Central Florida Res Found Inc Novel oncolytic viruses for sensitizing tumor cells to killing by natural killer cells
NZ759833A (en) * 2017-05-26 2023-01-27 Epicentrx Inc Recombinant adenoviruses carrying transgenes
CA3063652A1 (en) * 2017-06-01 2018-12-06 Psioxus Therapeutics Limited Oncolytic virus and method
US11573230B2 (en) * 2018-01-26 2023-02-07 Nantcell, Inc. Rapid verification of virus particle production for a personalized vaccine
GB201801614D0 (en) * 2018-01-31 2018-03-14 Psioxus Therapeutics Ltd Formulation
WO2019173334A1 (en) * 2018-03-05 2019-09-12 The Schepens Eye Research Institute, Inc. Engineered vegf variants for retinal neuroprotection, promotion of axon growth and axon regeneration
AU2019244150B2 (en) * 2018-03-30 2024-11-28 Tomoki Todo Swelling-suppressive oncolytic virus
WO2020052551A1 (en) * 2018-09-10 2020-03-19 Genesail Biotech (Shanghai) Co. Ltd. A modified oncolytic virus, composition and use thereof
AU2020232264B2 (en) * 2019-03-05 2026-02-19 Amgen Inc. Use of oncolytic viruses for the treatment of cancer
EP3725323A1 (en) * 2019-04-17 2020-10-21 Targovax Asa Oncolytic adenoviral vector expressing a member of the b7 family of costimulatory ligands and ada
IL288024B2 (en) 2019-05-14 2025-12-01 Provention Bio Inc Methods and compositions for preventing type
US20220249127A1 (en) * 2019-05-14 2022-08-11 Oncolys Biopharma Inc. Method for administering oncolytic virus to tumor tissue, and device for administration
GB201909081D0 (en) 2019-06-25 2019-08-07 Psioxus Therapeutics Ltd Method
US12006366B2 (en) 2020-06-11 2024-06-11 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
GB202102049D0 (en) * 2021-02-13 2021-03-31 Psioxus Therapeutics Ltd Viruses
MX2023013851A (es) 2021-05-24 2023-12-08 Provention Bio Inc Metodos para el tratamiento de diabetes tipo 1.
WO2022252185A1 (zh) * 2021-06-03 2022-12-08 上海允英生物医药科技有限公司 溶瘤病毒载体及其应用
JP2024536835A (ja) 2021-09-23 2024-10-08 サジタリウス バイオ，インコーポレーテッド アデノウイルス及びアデノウイルスの使用方法
US20250215452A1 (en) * 2022-03-25 2025-07-03 Universität Zürich Adenoviral Mediated Targeting of Activated Immune Cells
KR20260018078A (ko) 2023-05-25 2026-02-06 디스패치 바이오테라퓨틱스, 인크. 암을 치료하기 위한 표적으로서의 합성 암 항원
WO2025171383A2 (en) 2024-02-09 2025-08-14 Dispatch Biotherapeutics, Inc. Engineered cancer antigens and related methods and uses
WO2025171388A1 (en) 2024-02-09 2025-08-14 Dispatch Biotherapeutics, Inc. Engineered cancer antigens with modified domains and related methods and uses

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5358866A (en) 1991-07-03 1994-10-25 The United States Of America As Represented By The Department Of Health And Human Services Cytosine deaminase negative selection system for gene transfer techniques and therapies
US5801029A (en) 1993-02-16 1998-09-01 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
FR2705361B1 (fr) 1993-05-18 1995-08-04 Centre Nat Rech Scient Vecteurs viraux et utilisation en thérapie génique.
KR100356615B1 (ko) 1993-07-13 2003-04-03 아방티 파르마 소시에테 아노님 결함아데노바이러스벡터및유전자치료에서그의사용
US5631236A (en) 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
US5830686A (en) 1994-01-13 1998-11-03 Calydon Tissue-specific enhancer active in prostate
US5677170A (en) 1994-03-02 1997-10-14 The Johns Hopkins University In vitro transposition of artificial transposons
US5877011A (en) 1996-11-20 1999-03-02 Genzyme Corporation Chimeric adenoviral vectors
CN1242051A (zh) 1996-12-31 2000-01-19 昂尼克斯药物公司 用于肿瘤治疗和预防的致细胞病变病毒
US6420524B1 (en) 1997-02-20 2002-07-16 Johns Hopkins University School Of Medicine Gain of function mutations in ATP-dependent transposition proteins
US20030044384A1 (en) 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
US6291214B1 (en) 1998-05-11 2001-09-18 Glaxo Wellcome Inc. System for generating recombinant viruses
US20020019051A1 (en) 1998-05-27 2002-02-14 Monika Lusky Chimeric adenoviral vectors
US20030017138A1 (en) 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
CN1110553C (zh) 1998-07-15 2003-06-04 杭州赛狮生物技术开发有限公司 基因工程腺病毒及其用途
US6455314B1 (en) * 1998-09-11 2002-09-24 Genvec, Inc. Alternatively targeted adenovirus
PT1137792E (pt) * 1998-12-09 2007-08-10 Therion Biolog Corp Vector recombinado que exprime moléculas costimulantes múltiplas e as suas utilizações
DK1818408T3 (da) 1999-05-17 2011-10-17 Crucell Holland Bv Rekombinant adenovirus af serotypen Ad11
JP2003501041A (ja) 1999-06-01 2003-01-14 ユニバーシティ オブ ワシントン 細胞特異的な感染およびゲノム組み込みのためのキメラファイバータンパク質を発現する組換えアデノウイルスベクター
US7396679B2 (en) 1999-11-15 2008-07-08 Onyx Pharmaceuticals, Inc. Oncolytic adenovirus
PT1252322E (pt) 2000-01-21 2005-03-31 Biovex Ltd Estirpes de virus de herpes para terapia genica
US7456009B2 (en) 2000-03-07 2008-11-25 Merck & Co., Inc. Adenovirus formulations
JP2003534806A (ja) 2000-05-31 2003-11-25 ジェンベク、インコーポレイティッド アデノウイルスベクターのターゲティングの方法および組成物
WO2002053759A1 (en) 2001-01-04 2002-07-11 Wadell Goeran Viral vector for gene therapy
US20050175589A1 (en) * 2001-07-13 2005-08-11 Btg International Limited Anti-neoplastic viral agents
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
EP1327688A1 (en) 2002-01-14 2003-07-16 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Adenoviruses with enhanced lytic potency
EP1470233A1 (en) 2002-02-01 2004-10-27 Transgene S.A. Adenoviral vectors for modulating the cellular activities associated with pods
US20060147420A1 (en) 2004-03-10 2006-07-06 Juan Fueyo Oncolytic adenovirus armed with therapeutic genes
US7858367B2 (en) 2002-04-30 2010-12-28 Duke University Viral vectors and methods for producing and using the same
CN1705740B (zh) * 2002-10-15 2013-07-24 佩尔·松内·霍尔姆 具有反向基因表达的腺病毒及其应用
US20040167088A1 (en) 2003-02-25 2004-08-26 Genvec, Inc. Method of using adenoviral vectors with increased persistence in vivo
WO2004087930A1 (en) 2003-03-28 2004-10-14 Saint Louis University Adenovirus replication-competent vectors expressing trail
US20050136035A1 (en) * 2003-06-03 2005-06-23 Derek Ko Cell specific replication-competent viral vectors comprising a self processing peptide cleavage site
WO2005010149A2 (en) 2003-07-18 2005-02-03 Onyx Pharmaceuticals, Inc. Subgroup b adenoviral vectors for treating disease
US20050186178A1 (en) * 2003-08-28 2005-08-25 Ennist David L. Oncolytic adenoviral vectors encoding GM-CSF
WO2005107474A2 (en) 2004-04-30 2005-11-17 Introgen Therapeutics, Inc. Oncolytic adenovirus armed with therapeutic genes
CA2836987C (en) * 2004-05-26 2016-07-05 Psioxus Therapeutics Limited Chimeric adenoviruses for use in cancer treatment
CN100361710C (zh) 2004-06-07 2008-01-16 成都康弘生物科技有限公司 肿瘤细胞专一表达免疫调节因子gm-csf的溶瘤性腺病毒重组体的构建及其应用
US20060292682A1 (en) * 2004-07-22 2006-12-28 Hawkins Lynda K Addition of transgenes into adenoviral vectors
CN101068933A (zh) * 2004-08-25 2007-11-07 细胞基因系统有限公司 用于肿瘤细胞增强转导的纤维修饰的腺病毒载体
WO2006039045A2 (en) * 2004-09-01 2006-04-13 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adenoviral vectors able to transduce apcs, potential use in immune response generation
US20090208924A1 (en) 2004-12-01 2009-08-20 Bayer Schering Pharma Aktiengesellschaft Generation of Replication Competent Viruses for Therapeutic Use
WO2007027860A2 (en) 2005-08-31 2007-03-08 Genvec, Inc. Adenoviral vector-based malaria vaccines
DE102005055128B4 (de) 2005-11-15 2015-04-02 Universität Rostock Viraler Vektor, dessen Verwendung zur Therapie von Leberzellkarzinomen und pharmazeutische Mittel umfassend den Vektor
ES2304281B1 (es) 2006-02-01 2009-08-12 Dnatrix Inc. Adenovirus oncoliticos para el tratamiento del cancer.
JP5448840B2 (ja) 2006-12-22 2014-03-19 プシオクサス・セラピューティクス・リミテッド 腫瘍退縮アデノウイルスの作出およびその使用
US20110086005A1 (en) 2008-05-27 2011-04-14 Oncolytics Biotech Inc. Modulating interstitial pressure and oncolytic viral delivery and distribution
CN101381742A (zh) 2008-10-23 2009-03-11 浙江理工大学 晚期启动子靶向性调控溶瘤腺病毒pCN305载体及其构建方法与应用
ES2385251B1 (es) 2009-05-06 2013-05-06 Fundació Privada Institut D'investigació Biomèdica De Bellvitge Adenovirus oncolíticos para el tratamiento del cáncer.
EP2486137B1 (en) * 2009-10-05 2018-05-30 Ya-Fang Mei Replication-competent ad11p based viral vectors
WO2012024351A2 (en) 2010-08-16 2012-02-23 Salk Institute For Biological Studies Adenoviral assembly method
RU2013118724A (ru) * 2010-09-24 2014-10-27 Онкос Терапьютикс Ой Онколитические аденовирусные векторы и связанные с ними способы и применения
WO2012038606A1 (en) 2010-09-24 2012-03-29 Oncos Therapeutics Oy Oncolytic adenoviral vectors coding for monoclonal anti - ctla - 4 antibodies
WO2013074507A2 (en) 2011-11-14 2013-05-23 Regenerative Sciences, Llc Suspended particle delivery systems and methods
CN102586327B (zh) 2012-01-18 2013-09-11 陕西师范大学 一步法构建携带外源基因的d24纤维蛋白修饰的条件复制型腺病毒载体及其应用
WO2014138314A1 (en) 2013-03-05 2014-09-12 Baylor College Of Medicine Oncolytic virus
GB201322851D0 (en) 2013-12-23 2014-02-12 Psioxus Therapeutics Ltd Method
SI3021859T1 (en) 2013-10-25 2018-04-30 Psioxus Therapeutics Limited Oncolytic adenoviruses equipped with heterologous genes
KR20160137946A (ko) 2013-11-22 2016-12-02 디엔에이트릭스, 인코포레이티드 면역 세포 자극성 수용체 작용제(들)를 발현하는 아데노바이러스
GB201406608D0 (en) * 2014-04-12 2014-05-28 Psioxus Therapeutics Ltd Virus
GB201510197D0 (en) * 2014-06-12 2015-07-29 Psioxus Therapeutics Ltd Method of treating ovarian cancer
GB201503500D0 (en) 2015-03-02 2015-04-15 Ucl Business Plc Cell
WO2016146894A1 (en) 2015-03-17 2016-09-22 Tilt Biotherapeutics Oy Oncolytic adenoviruses coding for bi-specific antibodies and methods and uses related thereto
US11000559B2 (en) * 2015-04-30 2021-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding a B7 protein
CN108697745A (zh) 2015-12-17 2018-10-23 皮斯奥克斯治疗公司 编码抗tcr复合体抗体或片段的b组腺病毒
EP3430148A4 (en) 2016-03-18 2020-01-01 Nantcell, Inc. MULTIMODAL VECTOR FOR DENDRITIC CELL INFECTION
IL303187A (en) 2016-08-29 2023-07-01 Akamis Bio Ltd Adenovirus with bispecific T cell activator
GB201713765D0 (en) 2017-08-28 2017-10-11 Psioxus Therapeutics Ltd Modified adenovirus
EP3529361B1 (en) 2016-10-20 2021-03-24 Alpine Immune Sciences, Inc. Secretable variant immunomodulatory proteins and engineered cell therapy
WO2018083258A1 (en) 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding at least three transgenes
WO2018083257A1 (en) 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding transgenes
WO2018083259A1 (en) 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding transgenes
CA3063652A1 (en) * 2017-06-01 2018-12-06 Psioxus Therapeutics Limited Oncolytic virus and method
GB201801614D0 (en) 2018-01-31 2018-03-14 Psioxus Therapeutics Ltd Formulation

Also Published As

Publication number Publication date
CN108396015A (zh) 2018-08-14
JP2021176339A (ja) 2021-11-11
ZA201801589B (en) 2019-10-30
BR112017023171A2 (pt) 2018-07-17
JP7162929B2 (ja) 2022-10-31
SG11201708604TA (en) 2017-11-29
IL284375A (en) 2021-07-29
CN108396015B (zh) 2022-02-18
HUE048320T2 (hu) 2020-07-28
CA2984038A1 (en) 2016-11-03
PE20180241A1 (es) 2018-01-31
PL3288573T3 (pl) 2020-05-18
CN107690479B (zh) 2022-02-18
PH12017501942A1 (en) 2018-03-19
US10322152B2 (en) 2019-06-18
EP3288573A1 (en) 2018-03-07
US20190076493A1 (en) 2019-03-14
WO2016174200A1 (en) 2016-11-03
HRP20200439T1 (hr) 2020-06-12
AU2020223665A1 (en) 2020-09-10
EP3391892A1 (en) 2018-10-24
MY183703A (en) 2021-03-09
KR102643574B1 (ko) 2024-03-06
US20210338753A1 (en) 2021-11-04
IL258044A (en) 2018-05-31
JP2018514199A (ja) 2018-06-07
IL255286B (en) 2021-01-31
US20170056458A1 (en) 2017-03-02
SI3288573T1 (sl) 2020-06-30
AU2018201446B2 (en) 2020-05-28
AU2016256582A1 (en) 2017-11-16
EA201791971A1 (ru) 2018-04-30
SG10201901482XA (en) 2019-03-28
SA520412637B1 (ar) 2022-03-01
AU2018201446A1 (en) 2018-03-29
MX2017013684A (es) 2018-08-28
SG10201803081TA (en) 2018-06-28
JP6931229B2 (ja) 2021-09-01
CY1122833T1 (el) 2021-05-05
US20170266243A1 (en) 2017-09-21
US10548929B2 (en) 2020-02-04
CN107690479A (zh) 2018-02-13
US20180042973A1 (en) 2018-02-15
DK3288573T3 (da) 2020-03-16
US11000559B2 (en) 2021-05-11
IL255286A0 (en) 2017-12-31
BR122018004815A2 (pt) 2019-09-10
CL2018000587A1 (es) 2018-08-10
SMT202000222T1 (it) 2020-05-08
KR20240032177A (ko) 2024-03-08
SA517390260B1 (ar) 2021-11-10
EP3288573B1 (en) 2020-02-12
IL284375B (en) 2022-07-01
CA2984038C (en) 2023-01-03
AU2016256582B2 (en) 2020-10-29
EA037611B1 (ru) 2021-04-21
IL258044B (en) 2021-07-29
US20180140649A1 (en) 2018-05-24
PE20181140A1 (es) 2018-07-17
JP6928380B2 (ja) 2021-09-01
RS60105B1 (sr) 2020-05-29
AU2016256582A8 (en) 2018-01-18
KR20250134212A (ko) 2025-09-09
US10849945B2 (en) 2020-12-01
PT3288573T (pt) 2020-03-25
KR20180118249A (ko) 2018-10-30
KR102854512B1 (ko) 2025-09-04
LT3288573T (lt) 2020-03-25
ES2780366T3 (es) 2020-08-25
HK1249009A1 (en) 2018-10-26
JP2018139586A (ja) 2018-09-13
US10124028B2 (en) 2018-11-13
KR20180022638A (ko) 2018-03-06
CO2017010831A2 (es) 2018-02-28

Similar Documents

Publication Publication Date Title
CL2017002731A1 (es) Adenovirus oncolítico que codifica una proteína b7
CO2018005945A2 (es) Adenovirus del grupo b que codifica un anticuerpo contra el complejo tcr o fragmento de este
CL2019000167A1 (es) Novedosas proteínas de la cápside del virus adenoasociado.
PE20190563A1 (es) Genes de mini-distrofina optimizados y casetes de expresion y su uso
CL2019000392A1 (es) Métodos para detectar aav.
MX2024008058A (es) Adenovirus modificados.
CL2018001522A1 (es) Focalización de péptidos para dirigir virus adenoasociados (aavs)
UY35964A (es) Anticuerpos humanos para pd?1
MX2018007237A (es) Proteinas de cápside modificadas para un suministro mejorado de vectores de parvovirus.
MX384795B (es) Vectores que comprenden secuencias de polinucleotidos rellenadoras/de relleno y metodos de uso.
CO2018000134A2 (es) Factor ix modificado, y composiciones para la transferencia de genes a células, órganos y tejidos
MX2019006010A (es) Administracion viral de neoantigenos.
CL2017002422A1 (es) Derivados de maitansinoide, conjugados de los mismos, y métodos de uso.
ECSP17059343A (es) ARNi VARIANTE
MX382337B (es) Terapia génica de globina y uso de la misma para el tratamiento de hemoglobinopatias.
MX2019001672A (es) Composiciones de poxvirus quiméricos y usos de las mismas.
AR100419A1 (es) Vectores de virus adenoasociados para el tratamiento de trastornos de almacenamiento lisosómico
ECSP19018654A (es) Anticuerpos contra el virus del dengue, polipeptidos que contienen regiones fc variantes, y métodos de uso
IL270876A (en) Novel oncolytic viruses for sensitizing tumor cells to killing by natural killer cells
UY36522A (es) Ultracentrifugación analítica para la caracterización de partículas virales recombinantes
AR113134A1 (es) Arni variante
EA201890595A1 (ru) Онколитический аденовирус, кодирующий белок b7
MY185846A (en) Oncolytic adenovirus encoding a b7 protein
AR094912A1 (es) Vacuna contra el virus de la leucemia bovina
BR112019001737A2 (pt) expressão de pten-long com vírus oncolíticos